Skip to main content
Open Access Publications from the University of California


UCLA Previously Published Works bannerUCLA

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.

  • Author(s): Peterson, Benjamin E;
  • Bhatt, Deepak L;
  • Steg, Ph Gabriel;
  • Miller, Michael;
  • Brinton, Eliot A;
  • Jacobson, Terry A;
  • Ketchum, Steven B;
  • Juliano, Rebecca A;
  • Jiao, Lixia;
  • Doyle, Ralph T;
  • Granowitz, Craig;
  • Gibson, C Michael;
  • Pinto, Duane;
  • Giugliano, Robert P;
  • Budoff, Matthew J;
  • Tardif, Jean-Claude;
  • Verma, Subodh;
  • Ballantyne, Christie M;
  • REDUCE-IT Investigators
  • et al.


Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations.


REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigned statin-treated patients with elevated triglycerides (135-499 mg/dL), controlled low-density lipoprotein (41-100 mg/dL), and either established cardiovascular disease or diabetes plus other risk factors to receive icosapent ethyl 4 g/d or placebo. The primary and key secondary composite end points were significantly reduced. Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and revascularization subtypes.


A total of 8179 randomly assigned patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio, 0.66 [95% CI, 0.58-0.76]; P<0.0001; number needed to treat for 4.9 years=24); similar reductions were observed in total (first and subsequent) revascularizations (negative binomial rate ratio, 0.64 [95% CI, 0.56-0.74]; P<0.0001), and across elective, urgent, and emergent revascularizations. Icosapent ethyl significantly reduced percutaneous coronary intervention (hazard ratio, 0.68 [95% CI, 0.59-0.79]; P<0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95% CI, 0.45-0.81]; P=0.0005).


Icosapent ethyl reduced the need for first and subsequent coronary revascularizations in statin-treated patients with elevated triglycerides and increased cardiovascular risk. To our knowledge, icosapent ethyl is the first non-low-density lipoprotein-lowering treatment that has been shown to reduce coronary artery bypass grafting in a blinded, randomized trial. Registration: URL:; Unique identifier: NCT01492361.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View